A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-controlled Study of AG-120 in Previously-treated Subjects With Nonresectable or Metastatic Cholangiocarcinoma With an IDH1 Mutation
Phase of Trial: Phase III
Latest Information Update: 04 Oct 2017
At a glance
- Drugs Ivosidenib (Primary)
- Indications Cholangiocarcinoma
- Focus Registrational; Therapeutic Use
- Acronyms ClarIDHy
- Sponsors Agios Pharmaceuticals
- 06 Jun 2017 The ClarIDHy study is currently activated at participating sites in the US and will be activated in centers throughout Europe and in South Korea.
- 06 Jun 2017 Trial design presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
- 17 May 2017 According to an Agios Pharmaceuticals media release, data from this trial will be presented at the American Society of Clinical Oncology (ASCO) Annual meeting 2017.